Steady Expansion Forecast for Liver Cancer Diagnostics Market, Projected to Reach $13.71 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Liver Cancer Diagnostics Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for liver cancer diagnostics has seen significant expansion in the past few years. The market, which was valued at $9.69 billion in 2024, is expected to rise to $10.32 billion in 2025 with a compound annual growth rate (CAGR) of 6.5%. This robust growth can be attributed to factors such as the evolution of biopsy techniques and histopathology, detection of developing biomarkers, advent of screening programs, advancements in genetic testing, and enhancements in liver imaging methods.

Liver Cancer Diagnostics Market Size Forecast: What's the Projected Valuation by 2029?
In the coming years, the liver cancer diagnostics market is projected to experience significant growth, reaching a value of $13.71 billion in 2029 with a compound annual growth rate (CAGR) of 7.4%. The expansion during this forecast period can be linked to changes in regulation and standardization, increased use of imaging modalities, advancements in next-generation sequencing, promotion of broader screening programs and awareness, alongside a surge in the demand for biomarker-based tests. Key trends during the forecast period encompass an increase in incidence and prevalence, progress in imaging technologies, emphasis on non-invasive diagnostics, precision medicine, personalized diagnostics, and the incorporation of artificial intelligence (AI).

View the full report here:
https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

What Are the Drivers Transforming the Liver Cancer Diagnostics Market?
The liver cancer diagnostics market is projected to grow in response to the increasing prevalence of liver cancer. This disease, characterized by uncontrolled multiplication and growth of liver cells, poses a serious health risk. Diagnostic tests for liver cancer identify if the cancer cells are propogating within or around the liver following the initial cancer detection. Consequently, the increase in liver cancer incidences contributes to the upsurge in the demand for these diagnostics. Example being the report by the American Cancer Society, a voluntary health organization based in the US. Their Cancer Facts & Figures 2023 report, released in January 2023, recorded 13,230 new liver and intrahepatic bile duct cancer cases in women in the US in 2023, rising from 12,640 in 2020. Additionally, it is estimated there will be some 41,210 new cases of liver cancer in the US in 2023, with a predicted mortality of 29,380 people. Consequently, the soaring prevalence of liver cancer is enhancing the growth of the liver cancer diagnostic market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10481&type=smp

What Long-Term Trends Will Define the Future of the Liver Cancer Diagnostics Market?
Major companies in the liver cancer diagnostics market are creating highly sophisticated algorithms and assays based on biomarkers to enhance diagnostic precision and facilitate early detection. The term "biomarker-based assays and algorithms" refers to tools used in diagnosis that use specific biological indicators to pinpoint the presence of diseases, thus resulting in a more accurate and efficient diagnosis. For example, Roche Diagnostics, an American biotech company, rolled out the Elecsys PIVKA-II assay and the Elecsys GAAD algorithm in November 2023. The Elecsys PIVKA-II assay can detect increased levels of the PIVKA-II biomarker, which is linked with hepatocellular carcinoma (HCC), thus ameliorating the early detection of liver cancer in those at high risk. The Elecsys GAAD algorithm amalgamates multiple diagnostic markers such as PIVKA-II and AFP to augment diagnostic accuracy and simplify decision making in the detection of liver cancer.

Which Segments in the Liver Cancer Diagnostics Market Offer the Most Profit Potential?
The liver cancer diagnostics market covered in this report is segmented -

1) By Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Other Types
2) By Screening: Laboratory Testing, Imaging, Endoscopy, Biopsy, Other Screenings
3) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies
4) By End Use: Hospitals And Diagnostic Laboratories, Academic And Research Institutes, Pharmaceutical And CRO Laboratories

Subsegments:
1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma, Advanced-Stage Hepatocellular Carcinoma
2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma
3) By Hepatoblastoma: Pure Hepatoblastoma, Mixed Hepatoblastoma
4) Other Types: Secondary Liver Cancer, Fibrolamellar Carcinoma

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10481&type=smp

Which Firms Dominate the Liver Cancer Diagnostics Market by Market Share and Revenue in 2025?
Major companies operating in the liver cancer diagnostics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Siemens Healthineers, Illumina Inc., Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc., Danaher Corporation, Foundation Medicine Inc., Agilent Technologies Inc., Genemed Biotechnologies Inc., Merck KGaA, Fujifilm Medical Systems USA Inc., GE Healthcare, Advanced Cell Diagnostics Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories Inc., OncoCyte Corporation, Guardant Health Inc., Exact Sciences Corporation, Grail Inc., Freenome Holdings Inc., Natera Inc., Personal Genome Diagnostics Inc., Thrive Earlier Detection Corp

Which Regions Offer the Highest Growth Potential in the Liver Cancer Diagnostics Market?
North America was the largest region in the liver cancer diagnostics market in 2024. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10481

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay,
Americas: +1 310-496-7795,
Asia: +44 7882 955267 & +91 8897263534,
Europe: +44 7882 955267,
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.